Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.23 -0.23 (-0.47%)
Streaming Delayed Price Updated: 1:43 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
39 40 Next >
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains ↗
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5... 
Via Benzinga
News headline image
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati ↗
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes milestone payments and is expected to close by the end of 2024. 
Via Benzinga
News headline image
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses ↗
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization... 
Via Benzinga
News headline image
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. ↗
SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next ↗
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
News headline image
Week In Review: Zenas Raises $259 Million In IPO ↗
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... 
Via Talk Markets
Topics Initial Public Offering
News headline image
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease ↗
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3... 
Via Benzinga
News headline image
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent ↗
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
Via Investor's Business Daily
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs ↗
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to... 
Via Benzinga
News headline image
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... 
Via Benzinga
News headline image
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
News headline image
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
Via MarketBeat
News headline image
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences ↗
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease. 
Via Benzinga
News headline image
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval ↗
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the... 
Via Benzinga
News headline image
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices ↗
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access... 
Via Benzinga
Topics Lawsuit
News headline image
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows ↗
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years ↗
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Should You Buy Novavax Stock After This Regulatory Win? ↗
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
News headline image
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
News headline image
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease ↗
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. 
Via Benzinga
News headline image
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Despite its impressive fundamentals, NASDAQ:SNY remains undervalued. ↗
When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.